Nanopharm-logo-with-signature-Pantone (1)
Close this search box.

27 Sep 2023

Nanopharm Value Creation with OINDP Innovation


Nanopharm™, a leading contract research organization in the Orally Inhaled and Nasal Drug Products (OINDP) space, is revolutionizing the field of respiratory drug development. The company offers an integrated, one-stop solution that supports pre-clinical development programs through to clinic, catering to both established SMEs and emerging pharmaceutical companies. 


Nanopharm’s disruptive approach has provided unique opportunities for clients to build value and de-risk programs through innovation. The company’s SmartTrack™ service offers specialized understanding for product development programs from discovery to IND. Moreover, SmartTrack has unlocked the pathway for Q3 structural equivalence and in silico modelling of clinical pharmacokinetics for OINDPs.


The company’s core competence lies in integrating product development through device engineering, materials characterization, and formulation design. This has been further enhanced by a strategic alliance with Sciarra Laboratories (New York), offering the world’s leading fully integrated CDMO for the development and GMP manufacture of MDIs. This article showcases the expertise and innovative services that Nanopharm™ has to offer to those working in the exciting field of OINDP developments.

Related Posts


Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack

Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

Read More »